Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Global Market Opportunities And Strategies To 2033
Including: 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Etanercept Biosimilars; Trastuzumab Biosimilars2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies3) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis4) By Trastuzumab Biosimilars (By Application): Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric CancerCovering: Amgen Inc.; Samsung Biologics Co., Ltd.; Biocon Limited; C.H. Boehringer Sohn AG & Co. KG; Fresenius SE & Co. KGaA
Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global adalimumab, infliximab, etanercept and trastuzumab biosimilars market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for adalimumab, infliximab, etanercept and trastuzumab biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab, etanercept and trastuzumab biosimilars market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider adalimumab, infliximab, etanercept and trastuzumab biosimilars market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by product, by distribution channel and by application market.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the adalimumab, infliximab, etanercept and trastuzumab biosimilars market.
- Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by product, by distribution channel and by application in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for adalimumab, infliximab, etanercept and trastuzumab biosimilars providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Etanercept Biosimilars; Trastuzumab Biosimilars
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
4) By Trastuzumab Biosimilars (By Application): Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Other Trastuzumab Biosimilars Applications
Companies Mentioned: Amgen Inc.; Samsung Biologics Co., Ltd.; Biocon Limited; C.H. Boehringer Sohn AG & Co. KG; Fresenius SE & Co. KGaA
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; adalimumab, infliximab, etanercept and trastuzumab biosimilars indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- 1 Executive Summary
- 1.1 Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars – Market Attractiveness And Macro economic Landscape
- 2 Table Of Contents
- 3 List Of Tables
- 4 List Of Figures
- 5 Report Structure
- 6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market Definition And Segmentations
- 6.4 Market Segmentation By Product
- 6.4.1 Adalimumab Biosimilars
- 6.4.2 Infliximab Biosimilars
- 6.4.3 Etanercept Biosimilars
- 6.4.4 Trastuzumab Biosimilars
- 6.5 Market Segmentation By Distribution Channel
- 6.5.1 Hospital Pharmacies
- 6.5.2 Retail Pharmacies
- 6.5.3 Online Pharmacies
- 6.6 Market Segmentation By Application
- 6.6.1 Crohn's Disease
- 6.6.2 Psoriatic Arthritis
- 6.6.3 Rheumatoid Arthritis
- 6.6.4 Ulcerative Colitis
- 6.6.5 Ankylosing Spondylitis
- 6.6.6 Plaque Psoriasis
- 6.6.7 Other Applications
- 6.7 Trastuzumab Biosimilar Market Segmentation By Application
- 6.7.1 Adjuvant Breast Cancer
- 6.7.2 Metastatic Breast Cancer
- 6.7.3 Metastatic Gastric Cancer
- 6.7.4 Other Trastuzumab Biosimilars Applications
- 7 Major Market Trends
- 7.1 Demand For More Affordable Treatments For Autoimmune Disease
- 7.2 New Biosimilar Formulation To Enhance Patient Experience In Chronic Disease Treatment
- 7.3 Introduction Of A Cost-Effective Biosimilar For Autoimmune Diseases
- 7.4 New Citrate-Free Adalimumab Biosimilar Aims To Improve Patient Comfort
- 7.5 Merger And Acquisitions To Strengthen Market Position
- 8 Global Market Size And Growth
- 8.1 Market Size
- 8.2 Historic Market Growth, 2018 – 2023, Value ($ Million)
- 8.2.1 Market Drivers 2018 – 2023
- 8.2.2 Market Restraints 2018 – 2023
- 8.3 Forecast Market Growth, 2023 – 2028, 2033F Value ($ Million)
- 8.3.1 Market Drivers 2023 – 2028
- 8.3.2 Market Restraints 2023 – 2028
- 9 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market Segmentation
- 9.1 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 9.2 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 9.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 9.4 Global Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 10 Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Regional and Country Analysis
- 10.1 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 10.2 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11 Asia-Pacific Market
- 11.1 Summary
- 11.1.1 Market Overview
- 11.1.2 Region Information
- 11.1.3 Market Information
- 11.1.4 Background Information
- 11.1.5 Government Initiatives
- 11.1.6 Regulations
- 11.1.7 Regulatory Bodies
- 11.1.8 Major Associations
- 11.1.9 Taxes Levied
- 11.1.10 Corporate Tax Structure
- 11.1.11 Investments
- 11.1.12 Major Companies
- 11.2 Asia-Pacific Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.3 Asia-Pacific Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.4 Asia-Pacific Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.5 Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.6 Asia-Pacific Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market: Country Analysis
- 11.7 China Market
- 11.8 Summary
- 11.8.1 Market Overview
- 11.8.2 Country Information
- 11.8.3 Market Information
- 11.8.4 Background Information
- 11.8.5 Government Initiatives
- 11.8.6 Regulations
- 11.8.7 Regulatory Bodies
- 11.8.8 Major Associations
- 11.8.9 Taxes Levied
- 11.8.10 Corporate Tax Structure
- 11.8.11 Investments
- 11.8.12 Major Companies
- 11.9 China Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.10 China Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.11 China Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.12 China Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.13 India Market
- 11.14 India Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.15 India Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.16 India Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.17 India Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.18 Japan Market
- 11.19 Japan Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.20 Japan Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.21 Japan Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.22 Japan Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.23 Australia Market
- 11.24 Australia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.25 Australia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.26 Australia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.27 Australia Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.28 Indonesia Market
- 11.29 Indonesia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.30 Indonesia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.31 Indonesia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.32 Indonesia Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.33 South Korea Market
- 11.34 South Korea Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.35 South Korea Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.36 South Korea Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.37 South Korea Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12 Western Europe Market
- 12.1 Summary
- 12.1.1 Market Overview
- 12.1.2 Region Information
- 12.1.3 Market Information
- 12.1.4 Background Information
- 12.1.5 Government Initiatives
- 12.1.6 Regulations
- 12.1.7 Regulatory Bodies
- 12.1.8 Major Associations
- 12.1.9 Taxes Levied
- 12.1.10 Corporate Tax Structure
- 12.1.11 Investments
- 12.1.12 Major Companies
- 12.2 Western Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.3 Western Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.4 Western Europe Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.5 Western Europe Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.6 Western Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market: Country Analysis
- 12.7 UK Market
- 12.8 UK Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.9 UK Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.10 UK Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.11 UK Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.12 Germany Market
- 12.13 Germany Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.14 Germany Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.15 Germany Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.16 Germany Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.17 France Market
- 12.18 France Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.19 France Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.20 France Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.21 France Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.22 Italy Market
- 12.23 Italy Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.24 Italy Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.25 Italy Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.26 Italy Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.27 Spain Market
- 12.28 Spain Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.29 Spain Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.30 Spain Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.31 Spain Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13 Eastern Europe Market
- 13.1 Summary
- 13.1.1 Market Overview
- 13.1.2 Region Information
- 13.1.3 Market Information
- 13.1.4 Background Information
- 13.1.5 Government Initiatives
- 13.1.6 Regulations
- 13.1.7 Regulatory Bodies
- 13.1.8 Major Associations
- 13.1.9 Taxes Levied
- 13.1.10 Corporate Tax Structure
- 13.1.11 Investments
- 13.1.12 Major Companies
- 13.2 Eastern Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.3 Eastern Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.4 Eastern Europe Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.5 Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.6 Eastern Europe Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market: Country Analysis
- 13.7 Russia Market
- 13.8 Russia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.9 Russia Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.10 Russia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.11 Russia Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14 North America Market
- 14.1 Summary
- 14.1.1 Market Overview
- 14.1.2 Region Information
- 14.1.3 Market Information
- 14.1.4 Background Information
- 14.1.5 Government Initiatives
- 14.1.6 Regulations
- 14.1.7 Regulatory Bodies
- 14.1.8 Major Associations
- 14.1.9 Taxes Levied
- 14.1.10 Corporate Tax Structure
- 14.1.11 Investments
- 14.1.12 Major Companies
- 14.2 North America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.3 North America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.4 North America Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.5 North America Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.6 North America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market: Country Analysis
- 14.7 USA Market
- 14.8 Summary
- 14.8.1 Market Overview
- 14.8.2 Country Information
- 14.8.3 Market Information
- 14.8.4 Background Information
- 14.8.5 Government Initiatives
- 14.8.6 Regulations
- 14.8.7 Regulatory Bodies
- 14.8.8 Major Associations
- 14.8.9 Taxes Levied
- 14.8.10 Corporate Tax Structure
- 14.8.11 Investments
- 14.8.12 Major Companies
- 14.9 USA Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.10 USA Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.11 USA Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.12 USA Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.13 Canada Market
- 14.14 Canada Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.15 Canada Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.16 Canada Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.17 Canada Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15 South America Market
- 15.1 Summary
- 15.1.1 Market Overview
- 15.1.1 Region Information
- 15.1.2 Market Information
- 15.1.3 Background Information
- 15.1.4 Government Initiatives
- 15.1.5 Regulations
- 15.1.6 Regulatory Bodies
- 15.1.7 Major Associations
- 15.1.8 Taxes Levied
- 15.1.9 Corporate Tax Structure
- 15.1.10 Investments
- 15.1.11 Major Companies
- 15.2 South America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.3 South America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.4 South America Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.5 South America Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.6 South America Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market: Country Analysis
- 15.7 Brazil Market
- 15.8 Brazil Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.9 Brazil Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.10 Brazil Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.11 Brazil Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16 Middle East Market
- 16.1 Summary
- 16.1.1 Market Overview
- 16.1.2 Region Information
- 16.1.3 Market Information
- 16.1.4 Background Information
- 16.1.5 Government Initiatives
- 16.1.6 Regulations
- 16.1.7 Regulatory Bodies
- 16.1.8 Major Associations
- 16.1.9 Taxes Levied
- 16.1.10 Corporate Tax Structure
- 16.1.11 Investments
- 16.1.12 Major Companies
- 16.2 Middle East Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.3 Middle East Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.4 Middle East Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.5 Middle East Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17 Africa Market
- 17.1 Summary
- 17.1.1 Market Overview
- 17.1.2 Region Information
- 17.1.3 Market Information
- 17.1.4 Background Information
- 17.1.5 Government Initiatives
- 17.1.6 Regulations
- 17.1.7 Regulatory Bodies
- 17.1.8 Major Associations
- 17.1.9 Taxes Levied
- 17.1.10 Corporate Tax Structure
- 17.1.11 Investments
- 17.1.12 Major Companies
- 17.2 Africa Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17.3 Africa Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17.4 Africa Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17.5 Africa Trastuzumab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 18 Competitive Landscape And Company Profiles
- 18.1 Company Profiles
- 18.2 Amgen Inc
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Business Strategy
- 18.2.4 Financial Overview
- 18.3 Samsung Biologics Co., Ltd
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Business Strategy
- 18.3.4 Financial Overview
- 18.4 Biocon Limited
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Business Strategy
- 18.4.4 Financial Overview
- 18.5 C.H. Boehringer Sohn AG & Co. KG
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Business Strategy
- 18.5.4 Financial Overview
- 18.6 Fresenius SE & Co. KGaA
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Business Strategy
- 18.6.4 Financial Overview
- 19 Other Major And Innovative Companies
- 19.1 Pfizer Inc.
- 19.1.1 Company Overview
- 19.1.2 Products and Services
- 19.2 Teva Pharmaceutical Industries Ltd.
- 19.2.1 Company Overview
- 19.2.2 Products and Services
- 19.3 Celltrion Healthcare Co., Ltd
- 19.3.1 Company Overview
- 19.3.2 Products and Services
- 19.4 Intas Pharmaceuticals Limited
- 19.4.1 Company Overview
- 19.4.2 Products and Services
- 19.5 Sandoz Inc.
- 19.5.1 Company Overview
- 19.5.2 Products and Services
- 19.6 Hetero Drugs Ltd
- 19.6.1 Company Overview
- 19.6.2 Products and Services
- 19.7 Torrent Pharmaceuticals Ltd
- 19.7.1 Company Overview
- 19.7.2 Products and Services
- 19.8 Innovent Biologics (Suzhou) Co. Lt
- 19.8.1 Company Overview
- 19.8.2 Products and Services
- 19.9 Biocad
- 19.9.1 Company Overview
- 19.9.2 Products and Services
- 19.10 Reliance Industries Limited (Reliance Life Sciences)
- 19.10.1 Company Overview
- 19.10.2 Products and Services
- 19.11 Glenmark Pharmaceuticals Limited
- 19.11.1 Company Overview
- 19.11.2 Products and Services
- 19.12 Zydus Lifesciences Limited
- 19.12.1 Company Overview
- 19.12.2 Products and Services
- 19.13 Bio-Thera Solutions, Ltd
- 19.13.1 Company Overview
- 19.13.2 Products and Services
- 19.14 Cipla Limited
- 19.14.1 Company Overview
- 19.14.2 Products and Services
- 19.15 Coherus Biosciences Inc.
- 19.15.1 Company Overview
- 19.15.2 Products and Services
- 20 Competitive Benchmarking
- 21 Competitive Dashboard
- 22 Key Mergers And Acquisitions
- 22.1 Biothera Acquired Fresenius Kabi
- 22.2 Fresenius Kabi Acquired mAbxience
- 22.3 Biocon Biologics Acquired Viatris Biosimilars Business
- 22.4 Celltrion Acquired Assets Of Takeda Pharmaceuticals
- 22.5 Amgen Acquired Japanese JV with Astellas
- 22.6 True North Acquired Stake In Biocon Biologics Ltd.
- 23 Opportunities And Strategies
- 23.1 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market In 2028 – Countries Offering Most New Opportunities
- 23.2 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market In 2028 – Segments Offering Most New Opportunities
- 23.3 Global Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market In 2028 – Growth Strategies
- 23.3.1 Market Trend Based Strategies
- 23.3.2 Competitor Strategies
- 24 Adalimumab, Infliximab, Etanercept And Trastuzumab Biosimilars Market, Conclusions And Recommendations
- 24.1 Conclusions
- 24.2 Recommendations
- 24.2.1 Product
- 24.2.2 Place
- 24.2.3 Price
- 24.2.4 Promotion
- 24.2.5 People
- 25 Appendix
- 25.1 Geographies Covered
- 25.2 Market Data Sources
- 25.3 Research Methodology
- 25.4 Currencies
- 25.5 The Business Research Company
- 25.6 Copyright and Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook